Notice of AGM
6 June 2025
Cizzle Biotechnology Holdings plc
("Cizzle Biotechnology", or the "Company")
Notice of Annual General Meeting and Posting of Annual Report
Cizzle Biotechnology, the UK based diagnostics developer, announces that the notice of Annual General Meeting ("AGM") will be posted to shareholders today, along with the Company's Annual Report and Financial Statements for the year ended 31 December 2024 and will shortly be available for viewing on the Company's website at https://cizzlebiotechnology.com.
The AGM will be held at 11.00 a.m. on 30 June 2025 at the offices of Shakespeare Martineau LLP, 6th Floor, 60 Gracechurch Street, London, EC3V 0HR.
Enquiries:
|
Cizzle Biotechnology Holdings plc |
Via IFC Advisory |
|
Allan Syms (Executive Chairman) |
|
|
Allenby Capital Limited |
+44(0) 20 3328 5656 |
|
John Depasquale / Piers Shimwell (Corporate Finance) |
|
|
Stefano Aquilino / Amrit Nahal (Sales and Corporate Broking) |
|
|
IFC Advisory Limited |
+44(0) 20 3934 6630 |
|
|
Tim Metcalfe |
|
|
|
Florence Chandler |
|
|
About Cizzle Biotechnology
Based on the pioneering work of Professor Coverley and colleagues, on a naturally occurring variant of the cell nuclear protein CIZ1, the CIZ1B biomarker is highly associated with the presence of early-stage cancer. The company has developed CIZ1B into a non-invasive, cost-effective blood test to help in the early detection of lung cancer and has now entered commercial royalty-bearing arrangements to license its proprietary technology, and into collaborations with centres of excellence in cancer care. Cizzle was admitted to the Standard segment of the main market of the London Stock Exchange in May 2021.
For more information, please see https://cizzlebiotechnology.com
You can also follow the Company through its twitter account @CizzlePlc and on LinkedIn.